ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Johnson & Johnson pays $300m to develop cusatuzumab
December 07, 2018Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies. -
Ionis licenses another antisense GI drug to Janssen
November 20, 2017The candidate, IONIS-JBI2-2.5Rx, is orally delivered and acts on an undisclosed target to treat a gastrointestinal (GI) autoimmune disease. -
Bavarian Nordic and Janssen to develop vaccines against HIV-1 and hepatitis B
Danish biotechnology company Bavarian Nordic has entered an additional worldwide exclusive licence and collaboration agreement with Janssen Pharmaceuticals for the development of vaccine regimens against HIV-1 and hepatitis B.
Pharma Sources Insight January 2025
